{"id":"W4412014975","doi":"10.1177/20406207251342199","title":"Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AOP Orphan; Swedish Orphan Biovitrum; Novartis Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Celgene; Alexion Pharmaceuticals; Ariad Pharmaceuticals; Gilead Sciences; RWTH Aachen University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Phlebotomy; Internal medicine; Polycythemia vera; Thrombosis; Hematology; Retrospective cohort study; Myelofibrosis; Gastroenterology; Surgery; Bone marrow","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008043071,0.0004792247,0.001514411,0.0002023977,0.0001087354,0.00001354208,0.0003325139,0.0001803914,0.00006189715],"category_scores_gemma":[0.0008534862,0.0002757427,0.0001559177,0.0005930889,0.0001956268,0.00009178223,0.0001315226,0.0004242828,0.00002516029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001376793,"about_ca_system_score_gemma":0.000199718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004171328,"about_ca_topic_score_gemma":0.001656243,"domain_scores_codex":[0.9962878,0.0006604139,0.001247194,0.0008747062,0.0004217621,0.0005081185],"domain_scores_gemma":[0.9895106,0.008629901,0.0003208127,0.001124873,0.0002471432,0.0001666998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2087024,0.002595971,0.7724775,0.000009043789,0.0008599288,0.00004401672,0.002754008,0.00009693016,0.000003171329,0.0001168781,0.00002054284,0.01231956],"study_design_scores_gemma":[0.04030571,0.008209321,0.9470092,0.0002217209,0.000322399,0.000001752699,0.0009367248,0.00001716472,0.0006294166,0.0003178457,0.001784288,0.0002444728],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871146,0.00125775,0.0004208772,0.007382772,0.0004282783,0.00313346,0.0001546907,0.00004199068,0.00006555186],"genre_scores_gemma":[0.994081,0.0004923532,0.002047064,0.00243129,0.00005145006,0.0007591841,0.00002685888,0.00004124988,0.0000696163],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1745317,"threshold_uncertainty_score":0.9999695,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02571890817822953,"score_gpt":0.3605291126465878,"score_spread":0.3348102044683583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}